01 / DESIGN
What was studied?
A randomized, double-blind phase 3 trial enrolled 667 adults with overweight or obesity without type 2 diabetes. Researchers compared oral semaglutide with placebo for 68 weeks, with lifestyle intervention in both groups.
02 / FINDINGS
What did the researchers report?
The active group had greater average weight reduction and more participants met the prespecified weight-loss threshold. The publication also assessed adverse events and tolerability of the studied formulation.
03 / LIMITS
How should it be interpreted?
Absorption and formulation are central to interpreting an oral-peptide trial. This is not evidence that raw peptide material can reproduce the pharmaceutical product, or that oral and other formulations are interchangeable. The defined eligibility and follow-up also limit generalization.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.